Connection

Co-Authors

This is a "connection" page, showing publications co-authored by KELLY K HUNT and WILLIAM F SYMMANS.
Connection Strength

1.666
  1. Evaluation of Sensitivity to Endocrine Therapy Index (SET2,3) for Response to Neoadjuvant Endocrine Therapy and Longer-Term Breast Cancer Patient Outcomes (Alliance Z1031). Clin Cancer Res. 2022 08 02; 28(15):3287-3295.
    View in: PubMed
    Score: 0.212
  2. Long-Term Prognostic Risk After Neoadjuvant Chemotherapy Associated With Residual Cancer Burden and Breast Cancer Subtype. J Clin Oncol. 2017 Apr 01; 35(10):1049-1060.
    View in: PubMed
    Score: 0.145
  3. Cytoplasmic Cyclin E Predicts Recurrence in Patients with Breast Cancer. Clin Cancer Res. 2017 Jun 15; 23(12):2991-3002.
    View in: PubMed
    Score: 0.143
  4. The Neo-Bioscore Update for Staging Breast Cancer Treated With Neoadjuvant Chemotherapy: Incorporation of Prognostic Biologic Factors Into Staging After Treatment. JAMA Oncol. 2016 Jul 01; 2(7):929-36.
    View in: PubMed
    Score: 0.139
  5. Which threshold for ER positivity? a retrospective study based on 9639 patients. Ann Oncol. 2014 May; 25(5):1004-11.
    View in: PubMed
    Score: 0.118
  6. Classification of ipsilateral breast tumor recurrences after breast conservation therapy can predict patient prognosis and facilitate treatment planning. Ann Surg. 2011 Mar; 253(3):572-9.
    View in: PubMed
    Score: 0.096
  7. Higher parity and shorter breastfeeding duration: association with triple-negative phenotype of breast cancer. Cancer. 2010 Nov 01; 116(21):4933-43.
    View in: PubMed
    Score: 0.094
  8. Local, regional, and systemic recurrence rates in patients undergoing skin-sparing mastectomy compared with conventional mastectomy. Cancer. 2011 Mar 01; 117(5):916-24.
    View in: PubMed
    Score: 0.093
  9. Biologic and immunologic effects of preoperative trastuzumab for ductal carcinoma in situ of the breast. Cancer. 2011 Jan 01; 117(1):39-47.
    View in: PubMed
    Score: 0.093
  10. Long-term outcomes in patients with mucinous, medullary, tubular, and invasive ductal carcinomas after lumpectomy. Am J Surg. 2007 Oct; 194(4):527-31.
    View in: PubMed
    Score: 0.076
  11. Accuracy of the combination of mammography and sonography in predicting tumor response in breast cancer patients after neoadjuvant chemotherapy. Ann Surg Oncol. 2006 Nov; 13(11):1443-9.
    View in: PubMed
    Score: 0.071
  12. Tumor Biology and Response to Chemotherapy Impact Breast Cancer-specific Survival in Node-positive Breast Cancer Patients Treated With Neoadjuvant Chemotherapy: Long-term Follow-up From ACOSOG Z1071 (Alliance). Ann Surg. 2017 10; 266(4):667-676.
    View in: PubMed
    Score: 0.038
  13. Ten-Year Outcomes of Patients With Breast Cancer With Cytologically Confirmed Axillary Lymph Node Metastases and Pathologic Complete Response After Primary Systemic Chemotherapy. JAMA Oncol. 2016 Apr; 2(4):508-16.
    View in: PubMed
    Score: 0.034
  14. Relationship between Complete Pathologic Response to Neoadjuvant Chemotherapy and Survival in Triple-Negative Breast Cancer. Clin Cancer Res. 2016 Jan 01; 22(1):26-33.
    View in: PubMed
    Score: 0.033
  15. Sentinel lymph node surgery after neoadjuvant chemotherapy in patients with node-positive breast cancer: the ACOSOG Z1071 (Alliance) clinical trial. JAMA. 2013 Oct 09; 310(14):1455-61.
    View in: PubMed
    Score: 0.029
  16. USP-11 as a predictive and prognostic factor following neoadjuvant therapy in women with breast cancer. Cancer J. 2013 Jan-Feb; 19(1):10-7.
    View in: PubMed
    Score: 0.027
  17. A genomic predictor of response and survival following taxane-anthracycline chemotherapy for invasive breast cancer. JAMA. 2011 May 11; 305(18):1873-81.
    View in: PubMed
    Score: 0.024
  18. Predictors of tumor progression during neoadjuvant chemotherapy in breast cancer. J Clin Oncol. 2010 Apr 10; 28(11):1821-8.
    View in: PubMed
    Score: 0.022
  19. Phase I/II study of G3139 (Bcl-2 antisense oligonucleotide) in combination with doxorubicin and docetaxel in breast cancer. Clin Cancer Res. 2008 Dec 01; 14(23):7909-16.
    View in: PubMed
    Score: 0.021
  20. Metastases to the breast from nonbreast solid neoplasms: presentation and determinants of survival. Cancer. 2007 Aug 15; 110(4):731-7.
    View in: PubMed
    Score: 0.019
  21. Neoadjuvant therapy with paclitaxel followed by 5-fluorouracil, epirubicin, and cyclophosphamide chemotherapy and concurrent trastuzumab in human epidermal growth factor receptor 2-positive operable breast cancer: an update of the initial randomized study population and data of additional patients treated with the same regimen. Clin Cancer Res. 2007 Jan 01; 13(1):228-33.
    View in: PubMed
    Score: 0.018
  22. The safety of breast-conserving surgery in patients who achieve a complete pathologic response after neoadjuvant chemotherapy. Cancer. 2006 Sep 15; 107(6):1248-54.
    View in: PubMed
    Score: 0.018
  23. Use of lymphoscintigraphy defines lymphatic drainage patterns before sentinel lymph node biopsy for breast cancer. J Am Coll Surg. 2006 Jul; 203(1):64-72.
    View in: PubMed
    Score: 0.017
  24. Impact of concurrent proliferative high-risk lesions on the risk of ipsilateral breast carcinoma recurrence and contralateral breast carcinoma development in patients with ductal carcinoma in situ treated with breast-conserving therapy. Cancer. 2006 Jan 01; 106(1):42-50.
    View in: PubMed
    Score: 0.017
  25. Weekly paclitaxel improves pathologic complete remission in operable breast cancer when compared with paclitaxel once every 3 weeks. J Clin Oncol. 2005 Sep 01; 23(25):5983-92.
    View in: PubMed
    Score: 0.016
  26. Predictors of invasive breast cancer in patients with an initial diagnosis of ductal carcinoma in situ: a guide to selective use of sentinel lymph node biopsy in management of ductal carcinoma in situ. J Am Coll Surg. 2005 Apr; 200(4):516-26.
    View in: PubMed
    Score: 0.016
  27. Histologic localization of sentinel lymph node metastases in breast cancer. Am J Surg Pathol. 2003 Mar; 27(3):385-9.
    View in: PubMed
    Score: 0.014
  28. Intraoperative touch imprint of sentinel lymph nodes in breast carcinoma patients. Cancer. 2002 Aug 25; 96(4):225-31.
    View in: PubMed
    Score: 0.013
  29. Implications of axillary sentinel lymph node biopsy in immediate autologous breast reconstruction. Plast Reconstr Surg. 2002 May; 109(6):1888-96.
    View in: PubMed
    Score: 0.013
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.